Tobira Development (TBRA) Earning Somewhat Positive News Coverage, Report Finds
Media stories about Tobira Development (NASDAQ:TBRA) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tobira Development earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.6604503020018 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Tobira Development Company Profile
Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.
Receive News & Ratings for Tobira Development Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.